Table 3. Univariate and multivariate analyses of the prognostic indicators for disease-free survival and overall survival in patients with stage III colorectal cancer.
| Parameters | Disease-free Survival | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HRd (95% CIe) | p value | HRd (95% CIe) | p value | HRd (95% CIe) | p value | HRd (95% CIe) | p value | |
| Age (years) | ||||||||
| ≥65 vs <65 (80/98) | 0.686 (0.449–1.051) | 0.083 | 0.640 (0.396–1.034) | 0.068 | 0.525 (0.288–0.957) | 0.036* | 0.594 (0.305–1.157) | 0.126 |
| Gender | ||||||||
| Male vs Female (108/70) | 1.157 (0.753–1.776) | 0.506 | 0.910 (0.547–1.513) | 0.716 | 1.119 (0.624–2.008) | 0.705 | 0.784 (0.391–1.572) | 0.493 |
| Location | ||||||||
| Colon vs Rectum (147/31) | 0.732 (0.440 −1.217) | 0.229 | 0. 682 (0.366–1.270) | 0.228 | 1.030 (0.482–2.202) | 0.938 | 0.867 (0.349–2.153) | 0.759 |
| Tumor size | ||||||||
| ≥5 cm vs <5 cm (66/111) | 1.131 (0.739–1.733) | 0.571 | 1.099 (0.662–1.824) | 0.716 | 1.145 (0.644–2.035) | 0.644 | 0.791 (0.397–1.578) | 0.506 |
| Tumor depth | ||||||||
| T3 + T4 vs T1 + T2 (158/20) | 1.703 (0.786–3.689) | 0.177 | 1.311 (0.553–3.111) | 0.539 | 3.364 (0.816–13.861) | 0.093 | 2.424 (0.523–11.230) | 0.258 |
| Lymph Node metastasis | ||||||||
| N2 vs N1 (57/121) | 1.497 (0.973-2.303) | 0.067 | 1.096 (0.648–1.853) | 0.732 | 2.086 (1.182–3.682) | 0.011* | 1.418 (0.722–2.782) | 0.31 |
| Histology | ||||||||
| PD vs MD+WDb (22/155) | 1.357 (0.737-2.499) | 0.326 | 1.091 (0.517–2.303) | 0.82 | 1.639 (0.767–3.503) | 0.202 | 1.161 (0.433–3.109) | 0.767 |
| Vascular invasion | ||||||||
| Yes vs No (57/120) | 0.914 (0.582–1.437) | 0.698 | 0.791 (0.455–1.376) | 0.406 | 1.028 (0.558–1.893) | 0.93 | 0.757 (0.364–1.577) | 0.458 |
| Perineurial invasion | ||||||||
| Yes vs No (62/115) | 1.182 (0.770–1.813) | 0.444 | 1.058 (0.628–1.782) | 0.831 | 1.378 (0.772–2.458) | 0.278 | 1.064 (0.511–2.218) | 0.868 |
| Pre-op CEAc (ng/ml) | ||||||||
| ≥5/ vs <5 (78/93) | 1.282 (0.833–1.971) | 0.259 | 0.989 (0.588–1.664) | 0.967 | 1.114 (0.616–2.012) | 0.721 | 0.877 (0.423–1.818) | 0.725 |
| Post-op CEAc (ng/ml) | ||||||||
| ≥5 vs <5 (30/145) | 2.430 (1.482–3.985) | < 0.001* | 2.649 (1.414–4.964) | 0.002* | 2.171 (1.126–4.189) | 0.021* | 2.302 (0.945–5.604) | 0.066 |
| EGFR expression | ||||||||
| Positive vs Negative (108/65) | 2.615 (1.595–4.285) | < 0.001* | 2.485 (1.443–4.281) | 0.001* | 5.120 (2.166–12.102) | < 0.001* | 4.027 (1.625–9.977) | 0.003* |
aAJCC: American Joint Commission on Cancer; bPD: poorly differentiated, MD: moderately differentiated, WD: well differentiated; cCEA: carcinoembryonic antigen; dOR: odd ratio; eCI: confidence interval, *p < 0.05.